Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Adimab Announces New Antibody Discovery Collaboration with Celgene

Published: Thursday, August 22, 2013
Last Updated: Thursday, August 22, 2013
Bookmark and Share
Adimab will use its proprietary platform to generate therapeutic antibodies against multiple targets.

Adimab, LLC has announced a multi-target discovery collaboration with Celgene Corporation of Summit, NJ. Under terms of the Agreement, Adimab will use its proprietary platform to generate therapeutic antibodies against multiple targets.

Celgene will have the right to develop and commercialize all therapeutic antibodies resulting from the collaboration.

“We are very pleased to announce another major pharma partnership,” said Tillman Gerngross, CEO and co-founder of Adimab.

Gerngross continued, “Celgene has developed a highly successful oncology and inflammation franchise, and we are excited to partner with them to support their expanding antibody-based therapeutic portfolio.”

Adimab and Celgene have entered into a collaboration whereby Adimab will use its proprietary discovery and optimization platform to identify fully human antibodies against multiple targets.

For each target, the agreement grants Celgene the right to research antibodies generated during the collaboration for potential use as therapeutic products.

Under the terms of the Agreement, Adimab will receive an undisclosed upfront payment. In addition, for each target, Celgene will have the option to exclusively license antibodies
generated during the collaboration.

If Celgene exercises its option for a particular target, Adimab would receive license fees, clinical milestones and royalties on therapeutic product sales.

“The speed and technical superiority of our platform drives all of our deal flow,” said Guy Van Meter, Vice President of Business Development at Adimab. “The Adimab Platform is an extremely versatile antibody discovery and engineering tool that can be applied to a variety of different therapeutic development approaches, including IgG discovery, optimization, humanization, and bispecifics.”

Over the past four years, Adimab has established collaborations with multiple leading pharmaceutical companies, including Merck, Roche, Novartis, Eli Lilly, Genentech, Biogen Idec, Novo Nordisk, Gilead, Kyowa Hakko Kirin and GSK.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
'Fountain of Youth' Protein Points to Possible Human Health Benefit
Patients with higher blood levels of growth factor have lower risk of cardiovascular problems.
Lemon Juice and Human Norovirus
Citric acid may prevent the highly contagious norovirus from infecting humans, scientists discovered from the German Cancer Research Center.
Study Backs Flu Vaccinations for Elderly
Brown University researchers found vaccines well matched to the year’s flu strain significantly reduce deaths and hospitalizations compared to when the match is poor, suggesting that vaccination indeed makes a difference.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Protein Found to Play a Key Role in Blocking Pathogen Survival
Calprotectin fends off microbial invaders by limiting access to iron, an important nutrient.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!